Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company headquartered in Switzerland, dedicated to the development and commercialization of innovative medicines for rare diseases. Its primary focus lies in addressing unmet medical needs within the neuromuscular and pulmonary disease sectors, notably delivering therapeutic solutions for conditions such as Duchenne muscular dystrophy (DMD) and cystic fibrosis. A key asset in the company’s portfolio is Agamree (vamorolone), a first-in-class treatment offering an alternative to corticosteroids for DMD. Santhera engages in research and development as well as global partnerships, licensing vamorolone to partners in North America and China, underscoring its international reach. The company also has active programs targeting gene therapy for congenital muscular dystrophy, further broadening its therapeutic scope. Santhera’s operations and strategic collaborations position it as a significant player in the rare disease pharmaceutical landscape, serving patients with limited treatment options and making notable contributions to innovations in specialty medicine.